First patient dosed in phase 2 study for the treatment of hospitalized patients with acute lung injury caused by covid-19

Theravance Biopharma, Inc, a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines.

The initiation of the Phase 2 study in patients in the United Kingdom (UK) follows the successful completion of dosing in the Phase 1 study in healthy volunteers at the same clinical unit in the UK, allowing for a rapid transition to Phase 2.

The Phase 2 study consists of two parts. The first part will assess the safety, tolerability and clinical response to treatment in sequential ascending dose cohorts of hospitalized COVID-19 patients, with each patient being dosed for 7 days. Patients will be enrolled if they demonstrate hypoxia (lack of oxygen in the blood) as that is believed to be a marker of underlying hyperinflammation (cytokine storm) in the lung. More information can be found on, identifier number: NCT04402866.